Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

On the company’s earnings call yesterday, Chief Scientific Officer Dan Skrovronsky said it plans to start a Phase 3 trial of its GLP-1 pill, orforglipron, in hypertension. Lilly also plans to ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

While there are no studies documenting the number of physicians taking GLP-1s, a number of physicians told the Times that they've noticed many colleagues growing thinner and sharing similar eating ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...